Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

ClinicalTrials.gov ID: NCT04129164

Public ClinicalTrials.gov record NCT04129164. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).

Study identification

NCT ID
NCT04129164
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Amgen
Industry
Enrollment
183 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 9, 2019 (Actual)
Primary completion
Sep 1, 2022 (Actual)
Completion
Mar 10, 2023 (Actual)
Last update posted
Apr 30, 2025

2019 – 2023

United States locations

U.S. sites
16
U.S. states
9
U.S. cities
15
Facility City State ZIP Site status
Research Site Fullerton California 92835 —
Research site Upland California 91786 —
Research Site Lawrenceville Georgia 30046 —
Research Site Kansas City Kansas 66160 —
Research Site Baltimore Maryland 21224 —
Research Site Wheaton Maryland 20902 —
Research Site Boston Massachusetts 02111 —
Research Site Charlotte North Carolina 28204 —
Research Site Durham North Carolina 27710 —
Research Site Salisbury North Carolina 28144 —
Research Site Wilmington North Carolina 28401 —
Research site Duncansville Pennsylvania 16635 —
Research Site Memphis Tennessee 38119 —
Research site Dallas Texas 75231 —
Research Site Houston Texas 77084 —
Research Site Houston Texas 77089 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04129164, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 30, 2025 · Synced Oct 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04129164 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →